Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3098626 | 1.00 | GAA (0.74) | GAAMAPK1DGAT1MAPTTRPV1 | |
| SCHEMBL3092173 | 0.94 | GAA (0.69) | GAAMAPK1DGAT1MAPTTRPV1 | |
| SCHEMBL3103461 | 0.94 | GAA (0.69) | GAAMAPK1DGAT1MAPTTRPV1 | |
| SCHEMBL3087393 | 0.89 | DGAT1 (0.61) | GAADGAT1NPSR1CSGALNACT1 | |
| SCHEMBL3099766 | 0.89 | DGAT1 (0.61) | GAADGAT1NPSR1CSGALNACT1 | |
| SCHEMBL3096832 | 0.83 | PPARG (0.56) | GAADGAT1MAPTPPARGPPARA | |
| SCHEMBL3090986 | 0.83 | PPARG (0.56) | GAADGAT1MAPTPPARGPPARA | |
| SCHEMBL3218942 | 0.82 | NPSR1 (0.54) | GAADGAT1PPARGPPARANPSR1 | |
| SCHEMBL2298167 | 0.82 | CSGALNACT1 (0.75) | CSGALNACT1 | |
| SCHEMBL3100460 | 0.81 | DGAT1 (0.80) | DGAT1CSGALNACT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | claimed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | claimed |
| EP-1912634-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Healthcare, LLC (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007016538-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2007-02-08 | — | — | WO | claimed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | GAA 1025/4885MAPK1 3004/4885DGAT1 2018/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | GAA 1025/4885MAPK1 3004/4885DGAT1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.